ARCH Venture Partners

Kardigan is a pioneering heart health company dedicated to transforming cardiovascular drug development. It focuses on identifying and matching critical disease drivers with responsive patients from clinical trials, aiming to deliver curative medicines that go beyond symptom management, ultimately providing functional cures for cardiovascular diseases.

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Moleculent is a biotechnology company focused on advancing human health through the development of technology-enabled products that harness insights from the molecular foundations of human biology. By decoding human biology, the company aims to enhance therapies and diagnostics, thereby improving healthcare outcomes. Moleculent anticipates significant advancements in the understanding of molecular biology over the next decade, which will facilitate the creation of innovative treatments and diagnostic tools. Their mission centers on providing healthcare professionals with access to molecular science-based solutions that address various health challenges.

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

Basking Biosciences is a startup focused on developing a reversible thrombolytic therapy aimed at restoring blood flow to the brain during ischemic strokes, thereby preventing hemorrhage and minimizing long-term damage. The company’s innovative approach involves a paired therapy that combines an active agent targeting a crucial component of clot stability with a designed reversal agent. This reversal agent can be administered if bleeding occurs, effectively neutralizing the active compound and restoring the blood's normal clotting ability. By enabling healthcare professionals to treat acute ischemic stroke effectively, Basking Biosciences aims to improve patient outcomes in critical medical situations.

Accompany Health is a health technology platform that delivers comprehensive in-home care to patients, particularly in underserved regions. The company focuses on providing primary care services, including chronic illness management and treatment of new symptoms. It aims to support low-income patients with complex health needs throughout their care journeys, offering both at-home and virtual services. By fostering long-term relationships with patients, Accompany Health ensures that individuals receive continuous support, with access to care available at all hours. This approach eliminates the need for waiting rooms and enhances the overall patient experience by emphasizing dignity and accessibility in healthcare.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Gate Bioscience is a biotechnology company focused on developing small molecule drugs to selectively target and eliminate harmful extracellular proteins at their source within cells. The company's innovative approach combines a proprietary library of molecular gates, specialized assays, and deep expertise in secretory pathway biology, enabling precise, rapid, and repeatable drug discovery. This unique methodology allows Gate Bioscience to address a broad spectrum of diseases using a single therapeutic mechanism, with the potential to revolutionize the treatment of intractable diseases.

Magnet Biomedicine is a biotechnology research platform focused on the discovery of molecular glues. Utilizing its TrueGlue discovery platform, the company applies cutting-edge advancements in human biology and proteomics to identify specialized adhesives that enhance therapeutic effectiveness. These molecular glues are designed to optimize selectivity and promote biological synergy with specific targets, particularly in areas that have been difficult to address. Magnet Biomedicine aims to unlock the potential of TrueGlues to tackle a range of diseases, including cancer, cardiovascular conditions, and immune disorders, thereby enabling more effective and localized treatment options for challenging medical targets.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Myeloid Therapeutics is an immunology company dedicated to harnessing myeloid cells for the treatment of cancer and other diseases. The company employs its ATAK platform technology, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. This platform is designed to be versatile and scalable, allowing for the development of various treatment modalities across multiple disease areas. Currently, Myeloid Therapeutics is advancing a cell therapy program aimed at T cell lymphoma, as well as a primed monocyte approach for treating glioblastoma. Through its innovative technology, the company seeks to overcome the limitations of existing cell therapies and improve patient outcomes.

Orbital Therapeutics is focused on advancing global health through the development of RNA-based medicines aimed at treating various human diseases. The company is building an innovative platform that integrates established and emerging technologies, delivery mechanisms, and data analytics to create a diverse portfolio of therapeutics. Their efforts encompass a wide range of applications, including vaccines, immunomodulation, protein replacement, and regenerative medicine. By harnessing the full potential of RNA technology, Orbital Therapeutics seeks to provide patients with modern treatment options that were previously unavailable, thus enhancing the efficacy and accessibility of medical therapies.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Protillion Biosciences is a biotechnology company focused on transforming therapeutic antibody and drug discovery through innovative technology. It has developed a high-throughput protein engineering platform that aims to enhance the efficiency and effectiveness of protein-based drug design and development. By utilizing a novel protein display technology, Protillion seeks to improve the productivity of biologic research and development, enabling healthcare professionals to more rapidly discover and develop new protein therapeutics. The company's approach is intended to modernize traditional methods in the field, ultimately contributing to advancements in healthcare.

SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.

Human Immunology Biosciences is a biotechnology company dedicated to developing therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company specializes in precision medicine and focuses on discovering and creating transformative therapies. Its lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has demonstrated the ability to deplete CD38+ cells, including plasma cells and natural killer cells, in clinical studies. This mechanism may enhance clinical outcomes across a range of immune-mediated diseases, offering improved treatment options for patients suffering from these conditions.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Happy Health is a mission-driven technology company committed to transforming mental health awareness through the Happy Ring, the first wearable designed to measure your stress and mood 24/7.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

Pheast Therapeutics is a cancer immunotherapy company founded in 2020 and based in Palo Alto, California. The company specializes in developing innovative checkpoint therapies aimed at activating the innate immune system to combat cancer. Its primary focus is on creating immunotherapies that target macrophage checkpoints, which are crucial for enabling macrophages to effectively eliminate tumors in ovarian and breast cancers. By blocking these immune checkpoints, Pheast Therapeutics aims to enhance the likelihood of patient survival and advance treatment options within the healthcare sector.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.

Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. The organization seeks to develop innovative approaches to medicine that can reverse diseases, injuries, and disabilities. By uniting a community of prominent scientists, clinicians, and industry leaders, Altos Labs fosters collaboration across its operations in the San Francisco Bay Area, San Diego, and Cambridge, UK, while also engaging in significant partnerships in Japan. Through its research and initiatives, the company aspires to transform the landscape of medical treatment.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Walden Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative treatments for individuals with kidney disease. Founded by experts in renal disease, the company employs a systems-based approach to address the complex interplay between the pathology and biology of kidney conditions. Walden Biosciences targets specific biomarkers and enzymes, such as suPAR, an inflammatory marker linked to kidney function, and Dynamin, which plays a role in podocyte regeneration. Their goal is to create effective therapies for various kidney diseases, including chronic kidney disease and acute kidney injury, providing targeted treatment options that act directly at the site of drug action.

Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care, dermatology, animal health, eye care, and oral care. Based in Woodstock, Georgia, and incorporated in 1999, the company offers over 100 commercially available products worldwide. Its key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for managing dermatoses; Celacyn gel for scar management; and SebuDerm for seborrhea relief. Additionally, Sonoma provides Acuicyn for eye care, Microcyn for expedited wound healing, and various products targeting animal health, such as MicrocynAH and MicrocynVS. The company's focus on addressing unmet medical needs in chronic skin conditions significantly contributes to enhancing patient care while aiming to reduce overall healthcare costs. Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. and rebranded in December 2016.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

CERo Therapeutics, Inc. is a biotechnology company based in San Francisco, California, focused on advancing cellular immunotherapy. Established in 2016, the company has developed a hybrid platform that merges innate and adaptive immune responses to create engineered T-cell therapeutics for cancer treatment. This proprietary approach aims to harness the body's complete immune capabilities to enhance the effectiveness of cancer therapies. By integrating desirable features from both immune systems, CERo Therapeutics seeks to optimize treatment outcomes for patients with cancer.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Epirium Bio, Inc. is a San Diego-based biopharmaceutical company focused on developing therapeutic compounds for cardiovascular diseases, metabolic syndrome, and various conditions related to mitochondrial dysfunction. Founded in 2008 and previously known as Cardero Therapeutics, Epirium Bio utilizes innovative insights into mitochondrial biology and tissue regeneration to create small molecule therapies. The company's research is aimed at enhancing muscle strength and supporting the treatment of neuromuscular and neurodegenerative disorders, including conditions such as muscular dystrophy. Through its novel approaches, Epirium Bio seeks to provide clinically significant solutions for patients suffering from these challenging diseases.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

One BioMed is a molecular life science company focused on advancing human health through innovative biomedical research and testing solutions. The company develops a diagnostics testing platform that facilitates the purification and isolation of nucleic acids from various samples. Its technology integrates molecular diagnostic tools, including proprietary silicon biophotonics sensing technology, enabling physicians to effectively detect infectious diseases at the point of care. One BioMed's product offerings include DNA and RNA cartridge kits, designed to support its diagnostic capabilities and enhance the accuracy of testing in healthcare settings.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Rodeo Therapeutics Corp. is a drug development company based in Seattle, Washington, focused on creating novel small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Founded in 2017, the company specializes in targeting specific enzymes and biological pathways that are vital for tissue repair and regeneration. Its therapies work by increasing tissue levels of prostaglandin PGE2 through the inhibition of a prostaglandin-degrading enzyme, thereby facilitating tissue regeneration and protecting against conditions such as colitis. Rodeo Therapeutics is dedicated to advancing treatments that improve patient outcomes in various medical conditions related to tissue damage and recovery.

Mindstrong Health, established in 2013 and based in Mountain View, California, specializes in remote mental health care. It offers a digital therapeutic platform that combines AI-powered symptom tracking, evidence-based therapy, and psychiatry services. The platform provides structured, goal-oriented messaging sessions, covering areas such as cognitive behavioral therapy, psychoeducation, and crisis management. It aims to make mental health care more accessible and personalized, using passive data from human-computer interfaces to measure brain function and enable expert interventions.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. The company specializes in developing multi-functional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide aimed at crop protection, and BN2266, a fungicide that targets mRNA processing. Additionally, the company is working on a dual-function nematicide-fungicide for root protection and endo-parasiticides designed to overcome resistance. Boragen's innovative synthetic chemistry platform focuses on creating next-generation fungicides that support sustainable farming by minimizing the risk of fungicide resistance and reducing chemical usage while ensuring efficacy and performance.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.

Nohla Therapeutics, Inc. is focused on developing and manufacturing ex vivo expanded universal donor cellular therapies aimed at treating cancer and other life-threatening illnesses. The company utilizes a unique umbilical cord blood expansion platform to create and expand key cancer-fighting cells, enabling treatment without the need for HLA matching. Nohla's primary offerings include a Natural Killer (NK) cell program and a hematopoietic stem cell (HSC) expansion platform, which supports the clinical development of its flagship product, Dilanubicel. This off-the-shelf, ex vivo expanded hematopoietic stem and progenitor cell product is designed for immediate use to aid in hematopoietic recovery and address chemotherapy-induced neutropenia, among other indications. Founded in 2015 and based in Seattle, Washington, Nohla Therapeutics aims to streamline treatment processes while reducing patient risk and costs compared to traditional cell therapies.

Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at enhancing global access to biotherapeutics. The company focuses on innovative and integrated technologies that streamline the design, development, and manufacturing processes of biologics. Its key strengths lie in antibody discovery, molecular design, and the design of manufacturing processes and facilities. By leveraging scientific expertise and machine learning-driven technologies, Just Evotec Biologics provides clients with comprehensive solutions that accelerate biotherapeutic development while significantly lowering manufacturing costs.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Homology Medicines, Inc., established in 2015 and headquartered in Bedford, Massachusetts, is a biotechnology company focused on developing genetic medicines for patients with rare genetic diseases. The company's proprietary platform employs human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies or nuclease-free gene editing treatments in vivo, targeting various disease-relevant tissues such as the liver, central nervous system, and eye. Homology Medicines has two lead product candidates: HMI-102, currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, and HMI-103, intended for PKU treatment in pediatric patients. Additionally, the company is developing HMI-202 to treat metachromatic leukodystrophy. Homology Medicines aims to cure the underlying causes of these diseases by leveraging its robust intellectual property portfolio and experienced management team with a proven track record in rare disease therapeutics.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.